​

BioAge Labs (BIOA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BIOA Stock Forecast

BioAge Labs (BIOA) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $23.50, with a high of $40.00 and a low of $8.00. This represents a 295.62% increase from the last price of $5.94.

$5 $12 $19 $26 $33 $40 High: $40 Avg: $23.5 Low: $8 Last Closed Price: $5.94

BIOA Stock Rating

BioAge Labs stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (83.33%), 1 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 1 5 0 Strong Sell Sell Hold Buy Strong Buy

BIOA Price Target Upside V Benchmarks

TypeNameUpside
StockBioAge Labs295.62%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts139
Avg Price Target$8.00$18.00$30.78
Last Closing Price$5.94$5.94$5.94
Upside/Downside34.68%203.03%418.18%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26252--9
Sep, 26252--9
Aug, 26252--9
Jul, 26252--9
Jun, 26252--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 11, 2026Alice NettletonUBS$8.00$6.3426.18%34.68%
Jul 31, 2026Adam WalshRoth Capital$25.00$9.04176.55%320.88%
Jul 31, 2026Jefferies$21.00$9.40123.40%253.54%
May 27, 2026Adam WalshRoth Capital$36.00$16.20122.22%506.06%
May 13, 2026BTIG$40.00$18.19119.90%573.40%
Mar 27, 2026Needham$50.00$16.15209.60%741.75%
Feb 18, 2026Roger SongJefferies$62.00$19.63215.84%943.77%
Feb 04, 2026Morgan Stanley$23.00$19.9915.06%287.21%
Dec 05, 2025Morgan Stanley$12.00$11.405.26%102.02%
Mar 07, 2025Morgan Stanley$5.00$4.559.89%-15.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 11, 2026UBSNeutralinitialise
Jul 31, 2026Roth CapitalBuyBuyhold
May 27, 2026Roth CapitalBuyinitialise
May 13, 2026BTIGBuyinitialise
Mar 27, 2026NeedhamBuyinitialise
Feb 18, 2026JefferiesBuyBuyupgrade
Jan 27, 2026Piper SandlerOverweightinitialise
Dec 05, 2025Morgan StanleyOverweightReduceupgrade
Oct 29, 2025CitigroupBuyBuyhold
Oct 22, 2025CitigroupBuyBuyupgrade

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-6.63$-2.24--
Avg Forecast$-3.84$-1.95$-2.32$-1.75
High Forecast$-3.26$-1.29$-1.70$-1.75
Low Forecast$-4.41$-2.60$-2.94$-1.75
Surprise %72.66%14.87%--

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported-$8.99M--
Avg Forecast----
High Forecast----
Low Forecast----
Surprise %----

Net Income Forecast

$-85M $-69M $-53M $-37M $-21M $-5M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-71.11M$-80.61M--
Avg Forecast$-28.63M$-14.52M$-17.32M$-13.06M
High Forecast$-24.34M$-9.63M$-12.69M$-13.06M
Low Forecast$-32.92M$-19.41M$-21.95M$-13.06M
Surprise %148.39%455.15%--

BIOA Forecast FAQ

Is BioAge Labs stock a buy?

BioAge Labs stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioAge Labs is a favorable investment for most analysts.

What is BioAge Labs's price target?

BioAge Labs's price target, set by 6 Wall Street analysts, averages $23.5 over the next 12 months. The price target range spans from $8 at the low end to $40 at the high end, suggesting a potential 295.62% change from the previous closing price of $5.94.

How does BioAge Labs stock forecast compare to its benchmarks?

BioAge Labs's stock forecast shows a 295.62% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BioAge Labs over the past three months?

  • October 2026: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is BioAge Labs’s EPS forecast?

BioAge Labs's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.32, marking a 3.57% increase from the reported $-2.24 in 2025. Estimates for the following years are.

What is BioAge Labs’s revenue forecast?

BioAge Labs's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a -100.00% decrease from the reported $9M in 2025. The forecast for.

What is BioAge Labs’s net income forecast?

BioAge Labs's net income forecast for the fiscal year ending in December 2026 stands at $-17.319M, representing a -78.51% decrease from the reported $-80.605M in 2025. Projections indicate .